Literature DB >> 30981040

Association between prior somatic disease and 5-year relapse risk among 11,856 incident patients with schizophrenia.

Ole Köhler-Forsberg1, Holger J Sørensen2, Michael E Benros2, Liselotte Petersen3, Christiane Gasse4.   

Abstract

BACKGROUND: Somatic diseases have been associated with an increased risk for subsequent schizophrenia; however, it is unknown whether prior somatic diseases negatively affect early treatment outcomes after a first-time schizophrenia diagnosis.
METHODS: We included all individuals born in Denmark after January 1st, 1977 and first-time diagnosed with schizophrenia between January 1st, 1996 and December 31st, 2015. We identified all life-time somatic hospital contacts and all prescriptions within the year before the first-time schizophrenia diagnosis and followed patients for up to five years regarding risk for schizophrenia (re)-hospitalization (relapse). We performed Cox regression analyses calculating hazard rate ratios (HRR) including 95%-confidence intervals (CI) and adjusted for relevant confounders.
RESULTS: We followed a total of 11,856 patients with a first-time schizophrenia diagnosis (58.7% male, mean age 23.1 (SD = 4.7) years) for 39,033 person-years, whereof 5506 (46.4%) had relapse with schizophrenia re-hospitalization during 5-year of follow-up. Somatic hospital contacts ever before (95.4%; HRR = 1.30; 95%-CI = 1.07-1.59), and specifically during the year before schizophrenia diagnosis (42.5%; HRR = 1.36; 95%-CI = 1.11-1.66) were associated with an increased risk of schizophrenia relapse as were a greater number of prior somatic hospital contacts (p < 0.001). Individuals with up to four different prescriptions for somatic medications showed a trend towards a slightly lower risk of relapse.
CONCLUSION: Somatic diseases and health seeking patterns might have an impact on the course of schizophrenia, where severe somatic comorbidity, specifically during the year before first-time schizophrenia diagnosis, seem to negatively affect early treatment course, whereas previous somatic medication use may indicate a better compliance and help-seeking behavior.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Early intervention; Early onset schizophrenia; Epidemiology; Register-based; Relapse; Schizophrenia; Somatic comorbidity; Somatic diseases

Year:  2019        PMID: 30981040     DOI: 10.1016/j.eurpsy.2019.03.006

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  2 in total

Review 1.  Fear of relapse in schizophrenia: a mixed-methods systematic review.

Authors:  Stephanie Allan; Andrew Gumley; Zofia Zukowska; Emily Eisner; Li Ling
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-02-13       Impact factor: 4.519

2.  Free-of-charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications.

Authors:  Christopher Rohde; Mikkel Højlund; Christiane Gasse; Jesper Hallas; Ole Köhler-Forsberg
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-08-05       Impact factor: 3.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.